India Pharma Outlook Team | Friday, 19 December 2025
Senores Pharmaceuticals acquires Apnar Pharma in a Rs 91 crore deal, a move that strengthens its footprint across regulated global markets.
The company has signed a definitive agreement to acquire a 100 percent equity stake in Apnar Pharma Private Limited, along with five Abbreviated New Drug Applications (ANDAs), marking a major step in Senores’ international growth strategy.
Apnar Pharma, incorporated in December 2014, is a privately held generic drug company focused on licensing, development, and manufacturing for regulated markets such as the US, UK, and Canada.
The company operates a manufacturing facility in Jambusar, Gujarat, approved by the USFDA, UK MHRA, and Health Canada—an asset that significantly boosts Senores’ regulated-market capabilities.
Also Read: How a Culture of Thanks Fuels Retention in Hospitals
The total enterprise value of the transaction is about Rs 91 crore. This includes nearly Rs 76 crore in debt and expected liabilities tied to the manufacturing plant, which Senores will take over. The remaining Rs 15 crore will be paid in cash across two tranches, with 75 percent in the first tranche and 25 percent in the second. This equity outlay will be funded through IPO proceeds allocated for general corporate purposes and internal accruals.
Swapnil Shah, Promoter and Managing Director of Senores Pharmaceuticals, said, “This acquisition marks a significant milestone in accelerating the growth trajectory of Senores Pharmaceuticals Limited.”
In addition, Senores’ wholly owned subsidiary will acquire another basket of five ANDAs from Apnar Pharma’s parent company. Three of these are already validated and qualified, with commercialization expected to begin immediately. The first tranche is expected to close by March 2026, while the second is slated for Q2 FY 2027. The facility is expected to ramp up operations within one to three months, further reinforcing how Senores Pharmaceuticals acquires Apnar Pharma to scale faster in regulated markets.
